CU23237A1 - PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS - Google Patents
PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICASInfo
- Publication number
- CU23237A1 CU23237A1 CU20030285A CU20030285A CU23237A1 CU 23237 A1 CU23237 A1 CU 23237A1 CU 20030285 A CU20030285 A CU 20030285A CU 20030285 A CU20030285 A CU 20030285A CU 23237 A1 CU23237 A1 CU 23237A1
- Authority
- CU
- Cuba
- Prior art keywords
- formulations
- inducing
- nmb1125
- protein
- antigen
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 238000012163 sequencing technique Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Uso de un nuevo antígeno vacunal aplicado de manera preventiva o terapÉutica contra enfermedades bacterianas, virales, cancerosas, o de otro origen. El objetivo tÉcnico que se persigue es el desarrollo de formulaciones capaces de elevar el espectro protector de las vacunas ya existentes y extenderlo contra diferentes patogenos. Para lograr este objetivo se aislo e identifico la proteína NMB1125 como componente de las preparaciones de membrana externa de Neisseria meningitidis, capaz de inducir actividad bactericida. Adicionalmente, se clono y expreso el gen codificante para la proteína NMB1125, la cual se purifico evaluAndose luego se inmunogenicidad en biomodelos animales. El secuenciamiento de genes homologos evidencio, por su elevado grado de conservacion, su alto valor como antígeno inductor de una respuesta inmune cruzada cuando es presentado por diferentes vías. Las formulaciones resultantes de esta invencion son aplicables en la industria farmacÉutica como formulaciones vacUnales para uso humano.
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030285A CU23237A1 (es) | 2003-12-03 | 2003-12-03 | PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS |
| ARP040104481A AR047263A1 (es) | 2003-12-03 | 2004-12-01 | Proteina nmb1125 y su uso en formulaciones farmaceuticas |
| DE602004023419T DE602004023419D1 (de) | 2003-12-03 | 2004-12-02 | Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen |
| KR1020067010712A KR20060123759A (ko) | 2003-12-03 | 2004-12-02 | 단백질 ｎｍｂ1125 및 약학적 제제에서의 이들의 용도 |
| US10/580,508 US7691971B2 (en) | 2003-12-03 | 2004-12-02 | Protein NMB1125 and use thereof in pharmaceutical formulations |
| EP04802607A EP1693378B9 (en) | 2003-12-03 | 2004-12-02 | Protein nmb1125 and use thereof in pharmaceutical formulations |
| AU2004294376A AU2004294376A1 (en) | 2003-12-03 | 2004-12-02 | Protein NMB1125 and use thereof in pharmaceutical formulations |
| CNA2004800358779A CN1890260A (zh) | 2003-12-03 | 2004-12-02 | 蛋白质nmb1125及其在药物制剂中的用途 |
| CA002547317A CA2547317A1 (en) | 2003-12-03 | 2004-12-02 | Protein nmb1125 and use thereof in pharmaceutical formulations |
| PL04802607T PL1693378T3 (pl) | 2003-12-03 | 2004-12-02 | Białko NMB1125 i jego zastosowanie w kompozycjach farmaceutycznych |
| ES04802607T ES2334138T3 (es) | 2003-12-03 | 2004-12-02 | Proteina nmb1125 y uso de la misma en formulaciones farmaceuticas. |
| AT04802607T ATE444305T1 (de) | 2003-12-03 | 2004-12-02 | Nmb1125-protein und dessen verwendung in pharmazeutischen formulierungen |
| BRPI0417309-0A BRPI0417309A (pt) | 2003-12-03 | 2004-12-02 | proteìna nmb1125 e seu uso em formulações farmacêuticas |
| RU2006123434/13A RU2336900C2 (ru) | 2003-12-03 | 2004-12-02 | Белок nmb1125 и его применение в фармацевтических композициях |
| PCT/CU2004/000015 WO2005054281A2 (es) | 2003-12-03 | 2004-12-02 | Proteína nmb1125 y su uso en formulaciones farmaceuticas |
| NZ547520A NZ547520A (en) | 2003-12-03 | 2004-12-02 | Protein NMB1125 and use thereof in pharmaceutical formulations |
| ZA200604556A ZA200604556B (en) | 2003-12-03 | 2006-06-02 | Protein NMB 1125 and use thereof in pharmaceutical formulations |
| NO20063020A NO20063020L (no) | 2003-12-03 | 2006-06-28 | Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030285A CU23237A1 (es) | 2003-12-03 | 2003-12-03 | PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23237A1 true CU23237A1 (es) | 2007-09-26 |
Family
ID=40091628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20030285A CU23237A1 (es) | 2003-12-03 | 2003-12-03 | PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7691971B2 (es) |
| EP (1) | EP1693378B9 (es) |
| KR (1) | KR20060123759A (es) |
| CN (1) | CN1890260A (es) |
| AR (1) | AR047263A1 (es) |
| AT (1) | ATE444305T1 (es) |
| AU (1) | AU2004294376A1 (es) |
| BR (1) | BRPI0417309A (es) |
| CA (1) | CA2547317A1 (es) |
| CU (1) | CU23237A1 (es) |
| DE (1) | DE602004023419D1 (es) |
| ES (1) | ES2334138T3 (es) |
| NO (1) | NO20063020L (es) |
| NZ (1) | NZ547520A (es) |
| PL (1) | PL1693378T3 (es) |
| RU (1) | RU2336900C2 (es) |
| WO (1) | WO2005054281A2 (es) |
| ZA (1) | ZA200604556B (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117483A (en) * | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| CU22559A1 (es) * | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
| EP2261350A3 (en) * | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| DE60042114D1 (de) * | 1999-04-30 | 2009-06-10 | Craig J Venter Inst Inc | Genomische sequenzen von neisseria und verfahren zu ihrer verwendung |
| GB9911692D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic combinations |
| GB9911683D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
-
2003
- 2003-12-03 CU CU20030285A patent/CU23237A1/es unknown
-
2004
- 2004-12-01 AR ARP040104481A patent/AR047263A1/es unknown
- 2004-12-02 ES ES04802607T patent/ES2334138T3/es not_active Expired - Lifetime
- 2004-12-02 CN CNA2004800358779A patent/CN1890260A/zh active Pending
- 2004-12-02 AT AT04802607T patent/ATE444305T1/de not_active IP Right Cessation
- 2004-12-02 AU AU2004294376A patent/AU2004294376A1/en not_active Abandoned
- 2004-12-02 EP EP04802607A patent/EP1693378B9/en not_active Expired - Lifetime
- 2004-12-02 DE DE602004023419T patent/DE602004023419D1/de not_active Expired - Lifetime
- 2004-12-02 CA CA002547317A patent/CA2547317A1/en not_active Abandoned
- 2004-12-02 WO PCT/CU2004/000015 patent/WO2005054281A2/es not_active Ceased
- 2004-12-02 RU RU2006123434/13A patent/RU2336900C2/ru not_active IP Right Cessation
- 2004-12-02 US US10/580,508 patent/US7691971B2/en not_active Expired - Fee Related
- 2004-12-02 BR BRPI0417309-0A patent/BRPI0417309A/pt not_active IP Right Cessation
- 2004-12-02 KR KR1020067010712A patent/KR20060123759A/ko not_active Ceased
- 2004-12-02 PL PL04802607T patent/PL1693378T3/pl unknown
- 2004-12-02 NZ NZ547520A patent/NZ547520A/xx unknown
-
2006
- 2006-06-02 ZA ZA200604556A patent/ZA200604556B/xx unknown
- 2006-06-28 NO NO20063020A patent/NO20063020L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005054281A2 (es) | 2005-06-16 |
| CA2547317A1 (en) | 2005-06-16 |
| DE602004023419D1 (de) | 2009-11-12 |
| KR20060123759A (ko) | 2006-12-04 |
| ES2334138T3 (es) | 2010-03-05 |
| CN1890260A (zh) | 2007-01-03 |
| EP1693378B1 (en) | 2009-09-30 |
| AU2004294376A1 (en) | 2005-06-16 |
| PL1693378T3 (pl) | 2010-03-31 |
| EP1693378A2 (en) | 2006-08-23 |
| BRPI0417309A (pt) | 2007-09-11 |
| NO20063020L (no) | 2006-09-01 |
| ZA200604556B (en) | 2007-03-28 |
| AR047263A1 (es) | 2006-01-11 |
| RU2006123434A (ru) | 2008-01-10 |
| NZ547520A (en) | 2009-07-31 |
| EP1693378B9 (en) | 2010-05-19 |
| ATE444305T1 (de) | 2009-10-15 |
| US20070218000A1 (en) | 2007-09-20 |
| WO2005054281A3 (es) | 2005-08-04 |
| RU2336900C2 (ru) | 2008-10-27 |
| US7691971B2 (en) | 2010-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20111324A1 (no) | Rekombinant MVA-virus | |
| CY1118503T1 (el) | Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου | |
| CY1117757T1 (el) | Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους | |
| NO20054608L (no) | Influensavirusvaksine | |
| AR083561A1 (es) | Preparacion de una construccion antigenica | |
| CY1111916T1 (el) | Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος | |
| CL2009000445A1 (es) | Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion. | |
| WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
| CO6460752A2 (es) | Respuesta inmunitaria reforzada en especies aviares | |
| UA114286C2 (uk) | Спосіб лікування staphylococcus aureus | |
| AR046937A1 (es) | Proteina nmb0928 y su uso en formulaciones farmaceuticas | |
| DE60336588D1 (de) | Verbesserte anthraximpfstoffe und abgabeverfahren | |
| CU23237A1 (es) | PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS | |
| TW200505475A (en) | Avian E. coli vaccine for protection against colibacillosis | |
| CY1107560T1 (el) | Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο | |
| EA200700656A1 (ru) | Стабильные жидкие композиции плазмидной днк | |
| CU23435A1 (es) | Proteína nmb2134 y su uso en formulaciones farmacéuticas | |
| MX395737B (es) | Vacuna oral contra enfermedades respiratorias de ruminantes que contiene polivinilpirrolidona. | |
| CU23419A1 (es) | Proteína nmb0088 y su uso en formulaciones farmacéuticas | |
| WO2003101482A3 (en) | Liposome vaccine formulations for fin-fish | |
| BR112014007491A2 (pt) | sequências de aminoácidos para o controle de patógenos | |
| ATE457997T1 (de) | Impfstoff gegen burkholderia-infektionen | |
| TW200637573A (en) | Peptide for delivery of mucosal vaccines | |
| AR046921A1 (es) | Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes | |
| NO20084524L (no) | Farmasoytisk sammensetning inneholdende NMB0938-protein |